EUCTR2013-001322-26-DE进行中（未招募）1 期
A randomized, open-label, three-arm, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/OvCa to first line standard chemotherapy (carboplatin and paclitaxel) in women with newly diagnosed epithelial ovarian carcinoma
SOTIO a.s.0 个研究点目标入组 90 人开始时间: 2013年7月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Female aged =18 years
- •2. Patients with newly diagnosed, histologically confirmed, FIGO (Féderation Internationale de Gynécologie et d’Obstétrique) stage III epithelial ovarian, primary peritoneal or fallopian tube carcinoma (serous, endometrioid or mucinous) who have undergone initial surgery up to 3 weeks before randomization and are selected to receive first line Standard of Care chemotherapy (optional prolongation to 6 weeks after surgery)
- •3. Optimally debulked (zero residuum) or maximal residuum <1cm
- •4. Laboratory criteria:
- •~ White blood cells (WBC) >4,000/mm3 (4.0 x109/L)
- •~ Neutrophil count >1,500/mm3 (1.5 x109/L)
- •~ Hemoglobin (Hb) of at least 10g/dL (100g/L)
- •~ Platelet count of at least 100,000/mm3 (100 x109/L)
- •~ Total bilirubin within normal limits (benign hereditary hyperbilirubinemias, e.g. Gilbert´s syndrome are permitted)
- •~ Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <2x upper limit of normal (ULN), serum creatinine =2.0mg/dL
- •~ Blood Urea Nitrogen (BUN) <2.0x ULN
- •5. Adequate coagulation parameters
- •~ Activated partial thromboplastin time (APTT) =1.5x ULN and
- •~ International Normalized Ratio (INR) = 1.5
- •~ Post-operative treatment with low molecular weight heparin (LMWH) is acceptable
- •6. Life expectancy of at least 12 months based on Investigator’s judgment
- •7. Eastern Cooperative Oncology Group (ECOG) Performance status 0-2
- •8. Signed informed consent including patient’s ability to comprehend its contents
- •9. Females of childbearing potential (assessed by Investigator) must have had a negative serum pregnancy test at screening (ß-human chorionic gonadotropin [ß-HCG]).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •1. FIGO I,II,IV epithelial ovarian cancer
- •2. FIGO III clear cells epithelial ovarian cancer
- •3. Non-epithelial ovarian cancer, borderline tumors (tumors of low malignant potential)
- •4. Post-surgery residual disease with lesion(s) >1cm
- •5. Prior or current systemic anti-cancer therapy for ovarian cancer (for example chemotherapy, monoclonal antibody therapy [bevacizumab], tyrosine kinase inhibitor therapy, vascular endothelial growth factor [VEGF] therapy or hormonal therapy)
- •6. Previous or concurrent radiotherapy to the abdomen and pelvis
- •7. Malignancy other than epithelial ovarian cancer, except those that have been in CR for a minimum of 3 years, and except carcinoma in-situ of the cervix or non-melanoma skin carcinomas
- •8. Patient co-morbidities:
- •~ Human immunodeficiency virus (HIV) positive, human T lymphotropic virus (HTLV) positive
- •~ Active hepatitis B (HBV), active hepatitis C (HCV), active syphilis
- •~ Evidence of active bacterial, viral or fungal infection requiring systemic treatment
- •~ Clinically significant cardiovascular disease including:
- •o Symptomatic congestive heart failure
- •o Unstable angina pectoris
- •o Serious cardiac arrhythmia requiring medication
- •o Uncontrolled hypertension
- •o Myocardial infarction or ventricular arrhythmia or stroke within a 6 month period before inclusion, ejection fraction (EF) <40% or serious cardiac conduction system disorders, if a pacemaker is not present
- •~ Pericardial effusion of any National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) grade
- •~ Peripheral neuropathy having a CTCAE =Grade 2
- •~ Active autoimmune disease requiring treatment
- •~ History of severe forms of primary immune deficiencies
- •~ History of anaphylaxis or other serious reaction following vaccination
- •~ Uncontrolled co-morbidities including, psychiatric or social conditions which, in the Investigator’s opinion, would prevent participation in the trial
- •9. Known hypersensitivity to any constituent in the DCVAC/OvCa
- •10. Systemic immunosuppressive therapy for any reason
- •11. Refusal to sign the informed consent
- •12. Participation in a clinical trial using experimental therapy within the last 4 weeks prior study entry
- •13. Fertile woman of childbearing potential not willing to use highly effective method of contraception or combination of methods resulting into PEARL Index < 1 (implants, injectables, combination of oral contraceptives with intrauterine devices or barrier method of contraception or spermicidal jelly, vasectomized / sterilized partner or sexual abstinence) for the study duration and at least six months afterwards
- •14. Pregnant or lactating women
研究者
相似试验
进行中（未招募）
1 期
Evaluation of efficacy and safety of DCVAC/OvCa (therapeutic ovarian cancer vaccine) in women with newly diagnoses ovarian cancerEUCTR2013-001322-26-CZSOTIO a.s.120
进行中（未招募）
1 期
Evaluation of efficacy and safety of DCVAC/OvCa (therapeutic ovarian cancer vaccine) in women with newly diagnoses ovarian cancerepithelial ovarian carcinomaMedDRA version: 20.0Level: PTClassification code 10061328Term: Ovarian epithelial cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-001322-26-PLSOTIO a.s.120
进行中（未招募）
1 期
CLL11: A Study of RO5072759 With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic LeukemiaEUCTR2009-012476-28-EEF.Hoffmann-La Roche786
进行中（未招募）
1 期
CLL11: A Study of RO5072759 With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic LeukemiaEUCTR2009-012476-28-DKF.Hoffmann-La Roche786
进行中（未招募）
1 期
An open-label, multi-center, three arm randomized, phase III study to compare the efficacy and safety of RO5072759 + chlorambucil (GClb), rituximab + chlorambucil (RClb)or chlorambucil (Clb) alone in previously untreated CLL patients with comorbidities. - CLL11EUCTR2009-012476-28-ITF.Hoffmann-La Roche781